The short version of 反相色谱 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-20. Anything still debated is marked as such rather than presented as settled.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Point-of-care testing (POCT), also called near-patient testing or bedside testing, is defined as medical diagnostic testing at or near the point of care—that is, at the time and place of patient care. This contrasts with the historical pattern in which testing was wholly or mostly confined to the medical laboratory, which entailed sending off specimens away from the point of care and then waiting hours or days to learn the results, during which time care must continue without the desired information.
=== Other === a biodegradable de-icing agent. a catalyst in the Knoevenagel condensation and as a source of ammonia in the Borch reaction in organic synthesis. a protein precipitating reagent in dialysis to remove contaminants via diffusion. a reagent in agricultural chemistry for determination of soil CEC (cation exchange capacity) and determination of available potassium in soil wherein the ammonium ion acts as a replacement cation for potassium. part of Calley's method for lead artifact conservation
dihydrothymine dehydrogenase dihydrouracil dehydrogenase (NADP+) 4,5-dihydrothymine: oxidoreductase DPD DHPDH dehydrogenase, dihydrouracil (nicotinamide adenine dinucleotide, phosphate) DHU dehydrogenase hydropyrimidine dehydrogenase dihydropyrimidine dehydrogenase (NADP+)
It is a very specific tag that can be used for purification of membrane proteins. S-tag, a peptide derived from Ribonuclease A (KETAAAKFERQHMDS) SBP-tag, a peptide which binds to streptavidin (MDEKTTGWRGGHVVEGLAGELEQLRARLEHHPQGQREP) Softag 1, for mammalian expression (SLAELLNAGLGGS) Softag 3, for prokaryotic expression (TQDPSRVG) Spot-tag, a peptide recognized by a nanobody (PDRVRAVSHWSS) for immunoprecipitation, affinity purification, immunofluorescence and super resolution microscopy Strep-tag, a peptide which binds to streptavidin or the modified streptavidin called streptactin (Strep-tag II: WSHPQFEK) T7-tag, an epitope tag derived from the T7 major capsid protein of the T7 gene (MASMTGGQQMG). Used in different immunoassays as well as affinity purification Mainly used TC tag, a tetracysteine tag that is recognized by FlAsH and ReAsH biarsenical compounds (CCPGCC) Ty tag (EVHTNQDPLD) V5 tag, a peptide recognized by an antibody (GKPIPNPLLGLDST) VSV-tag, a peptide recognized by an antibody (YTDIEMNRLGK) Xpress tag (DLYDDDDK), a peptide recognized by an antibody
Another effect is the spin–orbit interaction, particularly spin–orbit splitting, which splits the 6d subshell—the azimuthal quantum number ℓ of a d shell is 2—into two subshells, with four of the ten orbitals having their ℓ lowered to 3/2 and six raised to 5/2. All ten energy levels are raised; four of them are lower than the other six. (The three 6d electrons normally occupy the lowest energy levels, 6d3/2.) A singly ionized atom of dubnium (Db+) should lose a 6d electron compared to a neutral atom; the doubly (Db2+) or triply (Db3+) ionized atoms of dubnium should eliminate 7s electrons, unlike its lighter homologs. Despite the changes, dubnium is still expected to have five valence electrons. As the 6d orbitals of dubnium are more destabilized than the 5d ones of tantalum, and Db3+ is expected to have two 6d, rather than 7s, electrons remaining, the resulting +3 oxidation state is expected to be unstable and even rarer than that of tantalum. The ionization potential of dubnium in its maximum +5 oxidation state should be slightly lower than that of tantalum and the ionic radius of dubnium should increase compared to tantalum; this has a significant effect on dubnium's chemistry. Atoms of dubnium in the solid state should arrange themselves in a body-centered cubic configuration, like the previous group 5 elements. The predicted density of dubnium is 21.6 g/cm3.
Sources: en.wikipedia.org
== Chemistry == Each amino acid has an amine group and a carboxylic group. Amino acids link to one another by peptide bonds which form through a dehydration reaction that joins the carboxyl group of one amino acid to the amine group of the next in a head-to-tail manner to form a polypeptide chain. The chain has two ends – an amine group, the N-terminus, and an unbound carboxyl group, the C-terminus. When a protein is translated from messenger RNA, it is created from N-terminus to C-terminus. The amino end of an amino acid (on a charged tRNA) during the elongation stage of translation, attaches to the carboxyl end of the growing chain. Since the start codon of the genetic code codes for the amino acid methionine, most protein sequences start with a methionine (or, in bacteria, mitochondria and chloroplasts, the modified version N-formylmethionine, fMet). However, some proteins are modified posttranslationally, for example, by cleavage from a protein precursor, and therefore may have different amino acids at their N-terminus.
== June 19, 1915 (Saturday) == A royal decree from Denmark allowed Iceland, still a Danish colony, to get its own flag. Born: Pat Buttram, American actor, best known for the role of Mr. Haney in the TV series Green Acres; as Maxwell Emmett Buttram, in Addison, Alabama, United States (d. 1994) Died: Benjamin F. Isherwood, 92, American naval officer, rear admiral and Engineer-in-Chief of the United States Navy, co-founder of the Bureau of Steam Engineering (b. 1822) Sergei Taneyev, Russian pianist and composer, best known for his opera Oresteia; died of a heart attack (b. 1856)
=== Bipolar disorder === Lithium is primarily used as a maintenance drug in the treatment of bipolar disorder to stabilize mood and prevent manic episodes. It is also effective in the acute treatment of manic episodes. It is effective for mania within the first 7 days of treatment. For acute treatment, although recommended by treatment guidelines for the treatment of depression in bipolar disorder, the evidence that lithium is superior to placebo for acute bipolar depression is low-quality. Atypical antipsychotics are considered more effective for treating acute bipolar depressive episodes. Lithium is effective for the long term prevention of bipolar depressive episodes. Lithium treatment was previously considered to be unsuitable for children, however more recent studies show its effectiveness for treatment of early-onset bipolar disorder in children as young as eight. The required dosage is slightly less than the toxic level (representing a low therapeutic index), requiring close monitoring of blood levels of lithium during treatment. Within the therapeutic range there is a dose-response relationship. A limited amount of evidence suggests lithium carbonate may contribute to the treatment of substance use disorders for some people with bipolar disorder. People with bipolar disorder are at a 3 times higher risk for dementia. Lithium reduces the risk of dementia by 50% among people with bipolar disorder.
== External links == Ferring Pharmaceuticals biography Archived 13 August 2010 at the Wayback Machine Ferring Pharmaceuticals Friends of the Royal Textile Academy of Bhutan Polypeptide Laboratories BV Nordic Pharmaceuticals BV Euro-Diagnostica BV Editions Paulsen
Sources: en.wikipedia.org
== Phytochemicals == Polyphenol research on maqui berries showed anthocyanin content to include eight glucoside pigments of delphinidin and cyanidin, with the principal anthocyanin being delphinidin 3-sambubioside-5-glucoside (34% of total anthocyanins). The average total anthocyanin content was 138 milligrams (2.13 gr) per 100 grams (3.5 oz) of fresh fruit, or 212 milligrams (3.27 gr) per 100 grams (3.5 oz) of dry fruit, ranking maqui berries low among darkly pigmented fruits for anthocyanin content (see table at anthocyanins). One study found that anthocyanins are also present in maqui leaves. Other phytochemicals extracted from the leaves were the alkaloids aristoteline, aristoquinoline, and aristone.
== Signs and symptoms == Children with sJIA are frequently severely unwell when diagnosed. They often have lost weight and are tired, feverish, experiencing myalgia and arthralgia, as well as occasional chest and stomach pain. These characteristics may overshadow the arthritis in the early stages of the disease. The presence of fever at presentation is practically universal in those with sJIA. The distinctive fever pattern associated with sJIA is characterized by temperatures that surge above 39 °C once or twice a day and then quickly fall to normal or below baseline. More than 80% of patients have a salmon-colored macular or maculopapular rash that appears along with their fever. Urticarial rash is less prevalent. The eruption is usually limited to the trunk, neck, and proximal extremities, but it might spread more widely. Macules typically measure less than 5 mm in diameter, while bigger macules may be present with center fading. The degree of erythema varies in the same patient, however, it is usually migratory and nonpruritic. The existence of arthritis must be validated before meeting the diagnostic criteria. Although arthralgias are often present at onset, arthritis may not be visible at first and can develop weeks, months, or even years later. Additionally, there is a wide range of joint involvement, from polyarticular patterns to oligoarticular patterns (four or fewer joints with arthritis). The wrists, knees, and ankles are the joints that are most frequently affected.
Half-Life: Blue Shift is an expansion pack for the first-person shooter video game Half-Life (1998). It was developed by Gearbox Software and published by Sierra On-Line. Blue Shift was the second expansion for Half-Life, originally intended as part of a Dreamcast port of Half-Life. Although the Dreamcast port was cancelled, the Windows version was released as a standalone product on June 12, 2001. As with Gearbox's previous expansion pack, Opposing Force (1999), Blue Shift returns to the setting and events of Half-Life, but portrays the story through the eyes of another character. Players control security guard Barney Calhoun, employed by the Black Mesa Research Facility, who must fight his way to safety during an alien invasion. Blue Shift also includes a graphics pack that upgrades the Half-Life models and textures. Blue Shift received mixed reviews. Many reviewers were critical of the short length and lack of new content, although the new graphics were praised.
==== Swan Shiratori ==== Cignian Swan Shiratori (チーニョ星人 白鳥 スワン, Chīnyo Seijin Shiratori Suwan) is Kruger's intellectually and technologically gifted assistant from Planet Cigno who provides the Dekarangers with their arsenal. While she possesses a variant of the SP License called the Swan License (スワンライセンス, Suwan Raisensu), which grants her the ability to transform into the orange-colored Deka Swan (デカスワン, Deka Suwan), she has a personal policy to only do so once every four years, except for emergencies. As Deka Swan, she can perform either the Swan Illusion (スワンイリュージョン, Suwan Iryūjon) attack or the Swan Rainbow (スワンレインボー, Suwan Reinbō) finisher. Swan Shiratori is portrayed by Mako Ishino (石野 真子, Ishino Mako).
== Etymology == The first written use of the term "vegetarian" originated in the early 19th century, when authors referred to a vegetable regimen diet. Historically, 'vegetable' could be used to refer to any type of edible vegetation. Modern dictionaries explain its origin as a compound of vegetable (adjective) and the suffix -arian (in the sense of agrarian). The term was popularized with the foundation of the Vegetarian Society in Manchester in 1847, although it has been in use since around 1839 to refer to what was previously called a vegetable regimen or diet. It was used in writing first attributed to actress, writer and abolitionist Fanny Kemble, in her Journal of a Residence on a Georgian plantation in 1838–1839. The earliest occurrences of the term seem to be related to Alcott House—a school on the north side of Ham Common, London—which was opened in July 1838 by James Pierrepont Greaves. From 1841, it was known as A Concordium, or Industry Harmony College, and the institution then began to publish its own pamphlet, The Healthian. It provides some of the earliest appearances of the term "vegetarian".
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.